Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Eli Lilly announces acquisition of Adverum Biotechnologies for up to $12.47 per share to advance Ixo-vec, a promising one-time gene therapy for age-related macular degeneration.
Novo Nordisk's chairman Helge Lund and six independent directors are stepping down after failing to reach agreement with majority shareholder over pace of board transformation as company faces market challenges.
WeightWatchers partners with Amazon Pharmacy to offer easier access to GLP-1 weight-loss drugs like Wegovy and Zepbound, especially for customers in rural areas with faster delivery options.
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
